



# Electrophysiological and neuroimaging tools to evaluate neurological symptoms, manifestations, and complications in patients with long COVID-19

Gustavo José Luvizutto<sup>1</sup> , Rodrigo Bazan<sup>2</sup>

<sup>1</sup>Department of Applied Physical Therapy, Federal University of Triangulo Mineiro, Uberaba, Minas Gerais, Brazil

<sup>2</sup>Department of Neurology, Psychology, and Psychiatry, Botucatu Medical School, Botucatu, São Paulo, Brazil

According to the latest literature, the SARS-CoV-2 virus is not confined to the respiratory tract, and can affect both the central (CNS) and the peripheral (PNS) nervous systems, leading to neurological symptoms, manifestations and complications after acute infection [1]. Systemic hematogenous or retrograde neuronal spreads are the main mechanisms contributing to short- and long-term neurological impairments after SARS-CoV-2 infection [2–4].

The main neurological symptoms include taste and olfactory dysfunction, myalgia, headache, altered mental status, confusion, delirium, and dizziness, which may present separately. Moreover, neurological manifestations and complications such as stroke, cerebral venous thrombosis, seizures, meningoencephalitis, Guillain–Barré syndrome, Miller Fisher syndrome, acute myelitis, and posterior reversible encephalopathy syndrome (PRES) have also been observed [5].

Clinical and structured assessments are critical to identify neurological impairments after COVID-19; however, several non-invasive neuroimaging techniques can be used to confirm findings on neurological examination, facilitate diagnosis, understand prognosis, and assist in long-term rehabilitation. Non-invasive brain imaging techniques can be classified into structure-based [e.g. computer tomography and magnetic resonance imaging (MRI)], metabolic-based (functional magnetic resonance imaging — fMRI, near-infrared spectroscopy — NIRS, etc.), and electrophysiological-based (mainly electro- and magneto-encephalography).

Structural and metabolic techniques are classically considered as having a very good spatial ‘resolution’ but a rather poor temporal one, while electrophysiological techniques are seen as having an excellent temporal resolution but a poor spatial one [6].


Among the neuroimaging techniques with high temporal resolution, electroencephalography (EEG) is mainly used in the evaluation of patients after COVID-19. EEG abnormalities are common in patients with COVID-19 and can be correlated with disease severity and pre-existing neurological conditions [7]. EEG studies focus on both cortical excitability (i.e. a qualitative study), and brain electrical activity patterns and their interference in cognitive behaviour (i.e. a quantitative study). Qualitative EEG studies have found frontal sharp waves in nearly all patients with COVID-19 who presented epileptiform discharges [8], bifrontal monomorphic diphasic periodic delta slow waves [9], diffuse background slowing, focal slowing, and frontal intermittent rhythmic delta activity (FIRDA) [10]. In addition, Gogia et al. [11] found that 50% of deceased patients had generalised diffuse severe slowing, indicating a global process. EEG abnormalities have been frequently observed in the frontal region and may serve as potential biomarkers of COVID-19 encephalopathy [7].

Concerning quantitative EEG studies, Cecchetti et al. [12] showed that patients with COVID-19 were characterised by a lower individual alpha frequency (power spectrum) compared to healthy subjects, and patients who showed stronger connectivity in the delta band at baseline concomitantly had better cognitive performance. Some authors have reported brainstem damage after COVID-19, mainly in the reticular activation system and cortical cholinergic projections, which have been previously related to changes in the tonic alpha rhythm in a healthy brain [13–16]. In addition, delta oscillations, especially in the anterior regions of the brain, have been associated with better performance on attention shifting and working memory tasks [17]. Based on nonlinear EEG features, Appelt et al. [18] observed a reduction in brain activity at rest

**Address for correspondence:** Gustavo José Luvizutto, Departamento de Fisioterapia da Universidade Federal do Triângulo Mineiro-UFTM, Frei Paulino St, 30-Bairro Abadia, 38025-180 Uberaba, Minas Gerais, Brazil; e-mail: gluvizutto@gmail.com

Received: 30.11.2022 Accepted: 02.12.2022 Early publication date: 14.12.2022

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.



**Figure 1.** Mechanisms of CNS and PNS infection by SARS-CoV-2, and main neuroimaging tools used for evaluation

in the F2–F4 areas and during high cognitive demands in the F3–F7 areas. In the COVID-19 group at 6–12 months after acute infection, a reduction in signal complexity was found in F3–F7 areas at rest. During the same period, cognitive function worsened, and correlations between nonlinear EEG features and cognitive tests were also observed [18].

Structural and functional brain images have also been used in several studies to understand the impact of SARS-CoV-2 infection on the brain. At the structural level, images can be evaluated through visual or quantitative inspection (volumetry), and previous findings have revealed a lower cortical volume in the orbitofrontal, frontal, and cingulate regions of patients with COVID-19 compared to controls. In addition, cerebrospinal fluid analysis has shown that regional grey matter volume and thickness decrease were negatively associated with neuroinflammation [19]. Multimodal brain imaging data, obtained as part of the UK Biobank imaging study, showed three main changes in SARS-CoV-2 cases: (1) a greater reduction in grey matter thickness and tissue contrast in the orbitofrontal cortex and parahippocampal gyrus; (2) greater changes in markers of tissue damage in regions functionally connected to the primary olfactory cortex; and (3) a greater reduction in global brain size [20]. At the functional level, studies have shown frontoparietal hypometabolism based on 18F-fluoro-2-deoxy-D-glucose, positron emission tomography (<sup>18</sup>FDG PET) analysis [21]. Esposito

et al. [22] showed that an increased functional segregation of the olfactory network around the anterior piriform cortex node, besides calibrating the clinically observable olfactory impairment, might eventually trigger a counteracting reaction to a more widespread neurological involvement.

These findings support the idea that the PNS should be systematically evaluated after COVID-19, using electrophysiological and structural techniques. Patients with COVID-19 more frequently present absent F waves, which has been attributed to motor neuron hypoexcitability [23], and many authors have reported myopathic patterns on electromyography (EMG), suggesting a direct action of COVID-19 on muscular fibres [24, 25]. In addition, peripheral nerve injury can occur secondarily to post-infectious inflammatory neuropathy, prone positioning-related stretch and/or compression injury, systemic neuropathy, or nerve entrapment from haematoma. Considering these cases, structural imaging, such as high-spatial-resolution MRI of peripheral nerves and high-spatial-resolution ultrasound, can be an excellent diagnostic tool [26].

A summary of the mechanisms of CNS and PNS infection by SARS-CoV-2, as well as the main neuroimaging tools used for evaluation, are described in Figure 1. It must be underlined that clinical and neurological assessments are essential at any stage of COVID-19, and that neuroimaging is a complementary set of techniques with the aim of understanding

the clinical evolution and prognosis of patients, in addition to providing readouts that may serve as potential biomarkers for neurodegenerative diseases occurring after COVID-19.

**Acknowledgments:** This study was conducted with the support of the National Council for Scientific and Technological Development (CNPq), Coordination for the Improvement of Higher Education Personnel, Ministry of Science, Technology, Innovations, and Communications (MCTIC), and Foundation for Research Support of the State of Minas Gerais.

**Conflicts of interests:** None.

**Funding:** Grants were received from the National Council for Scientific and Technological Development (CNPq), the Ministry of Science, Technology, Innovations, and Communications (MCTIC), and CNPq (Process 401192/2020-2).

## References

1. Leonardi M, Padovani A, McArthur JC. Neurological manifestations associated with COVID-19: a review and a call for action. *J Neurol*. 2020; 267(6): 1573–1576, doi: [10.1007/s00415-020-09896-z](https://doi.org/10.1007/s00415-020-09896-z), indexed in Pubmed: [32436101](#).
2. Zhou Z, Kang H, Li S, et al. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. *J Neurol*. 2020; 267(8): 2179–2184, doi: [10.1007/s00415-020-09929-7](https://doi.org/10.1007/s00415-020-09929-7), indexed in Pubmed: [32458193](#).
3. Desforges M, Le Coupanec A, Brison E, et al. Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. *Adv Exp Med Biol*. 2014; 807: 75–96, doi: [10.1007/978-81-322-1777-0\\_6](https://doi.org/10.1007/978-81-322-1777-0_6), indexed in Pubmed: [24619619](#).
4. Desforges M, Le Coupanec A, Dubeau P, et al. Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? *Viruses*. 2019; 12(1), doi: [10.3390/v12010014](https://doi.org/10.3390/v12010014), indexed in Pubmed: [31861926](#).
5. Harapan BN, Yoo HJ. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). *J Neurol*. 2021; 268(9): 3059–3071, doi: [10.1007/s00415-021-10406-y](https://doi.org/10.1007/s00415-021-10406-y), indexed in Pubmed: [33486564](#).
6. Burle B, Spieser L, Roger C, et al. Spatial and temporal resolutions of EEG: Is it really black and white? A scalp current density view. *Int J Psychophysiol*. 2015; 97(3): 210–220, doi: [10.1016/j.ijpsychoch.2015.05.004](https://doi.org/10.1016/j.ijpsychoch.2015.05.004), indexed in Pubmed: [25979156](#).
7. Antony AR, Haneef Z. Systematic review of EEG findings in 617 patients diagnosed with COVID-19. *Seizure*. 2020; 83: 234–241, doi: [10.1016/j.seizure.2020.10.014](https://doi.org/10.1016/j.seizure.2020.10.014), indexed in Pubmed: [33121875](#).
8. Galanopoulou AS, Ferastroarou V, Correa DJ, et al. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. *Epilepsia Open*. 2020; 17(5): 314–324, doi: [10.1002/epi4.12399](https://doi.org/10.1002/epi4.12399), indexed in Pubmed: [32537529](#).
9. Vellieux G, Rouvel-Tallec A, Jaquet P, et al. COVID-19 associated encephalopathy: Is there a specific EEG pattern? *Clin Neurophysiol*. 2020; 131(8): 1928–1930, doi: [10.1016/j.clinph.2020.06.005](https://doi.org/10.1016/j.clinph.2020.06.005), indexed in Pubmed: [32615526](#).
10. Bosak M, Mazurkiewicz I, Włoch-Kopeć D, et al. High prevalence of electroencephalographic frontal intermittent rhythmic delta activity in patients with moderately severe COVID-19. *Neurol Neurochir Pol*. 2022 [Epub ahead of print], doi: [10.5603/PJNNS.a2022.0069](https://doi.org/10.5603/PJNNS.a2022.0069), indexed in Pubmed: [36426929](#).
11. Gogia B, Thottempudi N, Ajam Y, et al. EEG characteristics in COVID-19 survivors and non-survivors with seizures and encephalopathy. *Cureus*. 2021; 13(10): e18476, doi: [10.7759/cureus.18476](https://doi.org/10.7759/cureus.18476), indexed in Pubmed: [34659916](#).
12. Cecchetti G, Agosta F, Canu E, et al. Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study. *J Neurol*. 2022; 269(7): 3400–3412, doi: [10.1007/s00415-022-11047-5](https://doi.org/10.1007/s00415-022-11047-5), indexed in Pubmed: [35249144](#).
13. Matschke J, Lütgehetmann M, Hagel C, et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. *Lancet Neurol*. 2020; 19(11): 919–929, doi: [10.1016/s1474-4422\(20\)30308-2](https://doi.org/10.1016/s1474-4422(20)30308-2).
14. Yong SJ. Persistent brainstem dysfunction in long-covid: a hypothesis. *ACS Chem Neurosci*. 2021; 12(4): 573–580, doi: [10.1021/acscchemneuro.0c00793](https://doi.org/10.1021/acscchemneuro.0c00793), indexed in Pubmed: [33538586](#).
15. Ricceri L, Minghetti L, Moles A, et al. Cognitive and neurological deficits induced by early and prolonged basal forebrain cholinergic hypo-function in rats. *Exp Neurol*. 2004; 189(1): 162–172, doi: [10.1016/j.expneuro.2004.05.025](https://doi.org/10.1016/j.expneuro.2004.05.025), indexed in Pubmed: [15296846](#).
16. Osipova D, Ahveninen J, Kaakkola S, et al. Effects of scopolamine on MEG spectral power and coherence in elderly subjects. *Clin Neurophysiol*. 2003; 114(10): 1902–1907, doi: [10.1016/s1388-2457\(03\)00165-2](https://doi.org/10.1016/s1388-2457(03)00165-2), indexed in Pubmed: [14499752](#).
17. Harmony T. The functional significance of delta oscillations in cognitive processing. *Front Integr Neurosci*. 2013; 7: 83, doi: [10.3389/fnint.2013.00083](https://doi.org/10.3389/fnint.2013.00083), indexed in Pubmed: [24367301](#).
18. Andrei Appelt P, Taciana Sisconetto A, Baldo Sucupira KS, et al. Changes in electrical brain activity and cognitive functions following mild to moderate COVID-19: a one-Year prospective study after acute infection. *Clin EEG Neurosci*. 2022; 53(6): 543–557, doi: [10.1177/15500594221103834](https://doi.org/10.1177/15500594221103834), indexed in Pubmed: [35635280](#).
19. Sanabria-Diaz G, Etter MM, Melie-Garcia L, et al. Brain cortical alterations in COVID-19 patients with neurological symptoms. *Front Neurosci*. 2022; 16: 992165, doi: [10.3389/fnins.2022.992165](https://doi.org/10.3389/fnins.2022.992165), indexed in Pubmed: [36340780](#).
20. Douaud G, Lee S, Alfaro-Almagro F, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. *medRxiv*. 2022; 604(7907): 697–707, doi: [10.1101/2021.06.11.21258690](https://doi.org/10.1101/2021.06.11.21258690), indexed in Pubmed: [34189535](#).
21. Hosp JA, Dressing A, Blazhenets G, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. *Brain*. 2021; 144(4): 1263–1276, doi: [10.1093/brain/awab009](https://doi.org/10.1093/brain/awab009), indexed in Pubmed: [33822001](#).
22. Esposito F, Cirillo M, De Micco R, et al. Olfactory loss and brain connectivity after COVID-19. *Hum Brain Mapp*. 2022; 43(5): 1548–1560, doi: [10.1002/hbm.25741](https://doi.org/10.1002/hbm.25741), indexed in Pubmed: [35083823](#).
23. Uncini A, Foresti C, Frigeni B, et al. Electrophysiological features of acute inflammatory demyelinating polyneuropathy associated with SARS-CoV-2 infection. *Neurophysiol Clin*. 2021; 51(2): 183–191, doi: [10.1016/j.neucli.2021.02.001](https://doi.org/10.1016/j.neucli.2021.02.001), indexed in Pubmed: [33685769](#).
24. Daia C, Scheau C, Neagu G, et al. Nerve conduction study and electromyography findings in patients recovering from Covid-19 – Case report. *Int J Infect Dis*. 2021; 103: 420–422, doi: [10.1016/j.ijid.2020.11.146](https://doi.org/10.1016/j.ijid.2020.11.146), indexed in Pubmed: [33217570](#).
25. Rosato C, Bolondi G, Russo E, et al. Clinical, electromyographical, histopathological characteristics of COVID-19 related rhabdomyolysis. *SAGE Open Med Case Rep*. 2020; 8: 2050313X20983132, doi: [10.1177/2050313X20983132](https://doi.org/10.1177/2050313X20983132), indexed in Pubmed: [33489234](#).
26. Fernandez CE, Franz CK, Ko JH, et al. Imaging review of peripheral nerve injuries in patients with COVID-19. *Radiology*. 2021; 298(3): E117–E130, doi: [10.1148/radiol.2020203116](https://doi.org/10.1148/radiol.2020203116), indexed in Pubmed: [33258748](#).